Understanding Triple Agonism: How Retatrutide Differs from Semaglutide and Tirzepatide

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide adds GIP receptor activity for dual agonism. Retatrutide adds glucagon receptor activity on top of both, making it a triple GLP-1 / GIP / glucagon agonist. The progression from single to triple receptor activity is the structural difference that distinguishes the three compounds and drives the steepening dose-response curve observed in published Phase 2 data.

What is the difference between single, dual, and triple agonism?

Each compound activates a different combination of three G-protein coupled receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor itself.

• Semaglutide — GLP-1 receptor agonist only. 31 amino acids, C18 fatty acid modification.
• Tirzepatide — Dual GLP-1 / GIP receptor agonist. 39 amino acids, engineered from a GIP backbone.
• Retatrutide — Triple GLP-1 / GIP / glucagon receptor agonist. 39 amino acids, C20 fatty diacid moiety.

Why glucagon receptor activation matters

The addition of glucagon receptor activity is what distinguishes Retatrutide. Glucagon, traditionally framed as the counter-regulatory hormone to insulin, also stimulates thermogenesis, lipolysis, hepatic fatty acid oxidation, and PCSK9 degradation. In a peptide that simultaneously enhances insulin secretion via GLP-1 and GIP, the glucagon component drives energy expenditure upward without producing the hyperglycaemic effects glucagon would cause in isolation.

Published clinical data

The clinical literature for all three compounds is now substantial. Semaglutide carries the longest track record (STEP and SUSTAIN trial programmes). Tirzepatide’s SURPASS programme established dual agonism as superior to single GLP-1 agonism for both glycaemic and weight outcomes.

Retatrutide Phase 2 data published in NEJM (Jastreboff et al., 2023) reported up to 24.2% mean body weight reduction at 48 weeks at the highest dose studied. A liver fat substudy demonstrated up to 82.4% reduction in hepatic fat content. The Phase 3 TRIUMPH programme is ongoing across 13 countries including Australia.

Structural engineering for half-life

Native GLP-1 has a circulating half-life under two minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). All three compounds are engineered to resist this degradation through a combination of DPP-4-resistant amino acid substitutions and fatty acid conjugation that promotes albumin binding.

Semaglutide carries a C18 fatty acid; Tirzepatide carries a C20 fatty acid via a different linker; Retatrutide carries a C20 fatty diacid moiety. The result: weekly dosing in clinical trials, with effective half-lives of approximately 7 days for Semaglutide, 5 days for Tirzepatide, and approximately 6 days for Retatrutide.

Research applications

For comparative in vitro work, the three compounds enable structure-activity relationship studies across the incretin receptor family. Side-by-side experiments using independently HPLC-verified material from a single source remove a major source of variability: differing supplier purity. All three are available in our research catalogue with batch-specific COAs.

Compliance reminder

All three compounds are supplied for in vitro laboratory and educational research only. None are listed on the ARTG. None are intended for human or animal consumption, therapeutic use, or diagnostic procedures.